The fundraising makes it the largest dedicated medtech fund in Europe and one of the largest pure medtech funds worldwide.
Advised by healthcare and technology investor Endeavour Vision Ltd, the specialist fund is targeting European and US companies in the medical device and digital health sectors with products that have gained regulatory approval and are already generating commercial traction. Endeavour Vision Ltd is an internationally-recognised investor in the healthcare and technology sectors. The team includes successful investment professionals and world-class industry veterans and has executed more than 65 investments within its areas of focus.
Bernard Vogel, Managing Partner of Endeavour Vision Ltd, adviser to the fund, said: "The medtech sector is evolving rapidly and presents very clear opportunities as we see life sciences and information technology converging in an incredible fashion. This successful fundraising is a strong endorsement of the team's solid track record and capabilities, as well as its strategy."
The Carey Olsen team was led by Partner David Crosland and included Senior Associates Jan Johannsson and Gemma Campbell.
Advocate Crosland said: "Fintech often grabs the headlines but medtech is a huge and growing market that is offering exciting opportunities for investors. We were very pleased to support Endeavour Vision on this highly successful fundraise."
The Ipes team was led by Andrew Whittaker and James Nicolle.
Mr Whittaker said: "Endeavour's continued confidence in Guernsey as a jurisdiction for their fund for the third time is a positive step forward. Using the National Private Placement Regime worked well and made their fund set up a smooth process. Ipes will be providing Endeavour with Administration, FATCA and AIFMD reporting services."
For more information about Guernsey's finance industry please visit www.guernseyfinance.com.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.